Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data

被引:9
作者
Ang, Geik Yong [1 ]
Yu, Choo Yee [1 ]
Subramaniam, Vinothini [1 ]
Khalid, Mohd Ikhmal Hanif Abdul [1 ]
Aziz, Tuan Azlin Tuan Abdu [1 ]
James, Richard Johari [1 ,2 ]
Ahmad, Aminuddin [3 ]
Rahman, Thuhairah Abdul [3 ]
Nor, Fadzilah Mohd [3 ]
Ismail, Adzrool Idzwan [1 ,4 ]
Isa, Kamarudzaman Md. [1 ,5 ]
Salleh, Hood [6 ]
Teh, Lay Kek [1 ,2 ]
Salleh, Mohd Zaki [1 ,2 ]
机构
[1] Univ Teknol MARA Selangor UiTM, Integrat Pharmacogen Inst iPROMISE, Puncak Alam, Selangor, Malaysia
[2] Univ Teknol MARA Selangor UiTM, Fac Pharm, Puncak Alam, Selangor, Malaysia
[3] Univ Teknol MARA Selangor UiTM, Fac Med, Puncak Alam, Selangor, Malaysia
[4] Univ Utara Malaysia, Coll Arts & Sci, Sintok, Kedah, Malaysia
[5] Univ Selangor, Fac Commun & Media, Shah Alam, Malaysia
[6] Univ Kebangsaan Malaysia, Inst Alam Sekitar & Pembangunan LESTARI, Bangi, Selangor, Malaysia
来源
PLOS ONE | 2016年 / 11卷 / 10期
关键词
CLOPIDOGREL-TREATED PATIENTS; CYP2C19-ASTERISK-17; ALLELE; CYTOCHROME-P450; ENZYMES; OMEPRAZOLE METABOLISM; PLATELET-AGGREGATION; POLYMORPHISMS; PHARMACOGENETICS; ANTIDEPRESSANTS; GENOTYPES; IDENTIFICATION;
D O I
10.1371/journal.pone.0164169
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The human cytochrome P450 (CYP) is a superfamily of enzymes that have been a focus in research for decades due to their prominent role in drug metabolism. CYP2C is one of the major subfamilies which metabolize more than 10% of all clinically used drugs. In the context of CYP2C19, several key genetic variations that alter the enzyme's activity have been identified and catalogued in the CYP allele nomenclature database. In this study, we investigated the presence of well-established variants as well as novel polymorphisms in the CYP2C19 gene of 62 Orang Asli from the Peninsular Malaysia. A total of 449 genetic variants were detected including 70 novel polymorphisms; 417 SNPs were located in introns, 23 in upstream, 7 in exons, and 2 in downstream regions. Five alleles and seven genotypes were inferred based on the polymorphisms that were found. Null alleles that were observed include CYP2C19*3 (6.5%), *2 (5.7%) and *35 (2.4%) whereas allele with increased function *17 was detected at a frequency of 4.8%. The normal metabolizer genotype was the most predominant (66.1%), followed by intermediate metabolizer (19.4%), rapid metabolizer (9.7%) and poor metabolizer (4.8%) genotypes. Findings from this study provide further insights into the CYP2C19 genetic profile of the Orang Asli as previously unreported variant alleles were detected through the use of massively parallel sequencing technology platform. The systematic and comprehensive analysis of CYP2C19 will allow uncharacterized variants that are present in the Orang Asli to be included in the genotyping panel in the future.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] A method and server for predicting damaging missense mutations
    Adzhubei, Ivan A.
    Schmidt, Steffen
    Peshkin, Leonid
    Ramensky, Vasily E.
    Gerasimova, Anna
    Bork, Peer
    Kondrashov, Alexey S.
    Sunyaev, Shamil R.
    [J]. NATURE METHODS, 2010, 7 (04) : 248 - 249
  • [2] Andrews S., 2010, FASTQC QUALITY CONTR
  • [3] Increased omeprazole metabolism in carriers of the CYP2C19*17 allele;: a pharmacokinetic study in healthy volunteers
    Baldwin, R. Michael
    Ohlsson, Staffan
    Pedersen, Rasmus Steen
    Mwinyi, Jessica
    Ingelman-Sundberg, Magnus
    Eliasson, Erik
    Bertilsson, Leif
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) : 767 - 774
  • [4] Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: A retrospective analysis
    Barak, Yoram
    Swartz, Marnina
    Baruch, Yehuda
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (07) : 1744 - 1747
  • [5] Haploview: analysis and visualization of LD and haplotype maps
    Barrett, JC
    Fry, B
    Maller, J
    Daly, MJ
    [J]. BIOINFORMATICS, 2005, 21 (02) : 263 - 265
  • [6] Identification and functional characterization of new potentially defective alleles of human CYP2C19
    Blaisdell, J
    Mohrenweiser, H
    Jackson, J
    Ferguson, S
    Coulter, S
    Chanas, B
    Xi, T
    Ghanayem, B
    Goldstein, JA
    [J]. PHARMACOGENETICS, 2002, 12 (09): : 703 - 711
  • [7] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    Brandt, J. T.
    Close, S. L.
    Iturria, S. J.
    Payne, C. D.
    Farid, N. A.
    Ernest, C. S., II
    Lachno, D. R.
    Salazar, D.
    Winters, K. J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) : 2429 - 2436
  • [8] Caudle K. E., 2016, GENET MED
  • [9] Cavallari Larisa H, 2012, J Pharm Pract, V25, P413, DOI 10.1177/0897190012448311
  • [10] The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19☆35 and CYP2C19☆2 Alleles
    Chaudhry, Amarjit S.
    Prasad, Bhagwat
    Shirasaka, Yoshiyuki
    Fohner, Alison
    Finkelstein, David
    Fan, Yiping
    Wang, Shuoguo
    Wu, Gang
    Aklillu, Eleni
    Sim, Sarah C.
    Thummel, Kenneth E.
    Schuetz, Erin G.
    [J]. DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1226 - 1235